Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development

Drug Metabolism and Disposition

Volumn 29, Issue 4 II, 2001, Pages 570-573

  Ingelman Sundberg, M ^a  

^a Division of Molecular Toxicology   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DRUG;

ALLELE; AMINO ACID SUBSTITUTION; CONFERENCE PAPER; DRUG ABSORPTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; GENE AMPLIFICATION; GENE DUPLICATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HUMANS; POLYMORPHISM, GENETIC;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0035062413     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Relationship of polymorphisms in the cytochrome P450 CYP29 to warfarin dose requirement and risk for bleeding complications
2. Pharmacokinetics and effect an caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
3. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects
4. Individual differences in nicotine kinetics and metabolism in humans
5. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
6. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine
7. Pharmacogenomics: Translating functional genomics into rational therapeutics
8. Detection and characterization of novel polymorphisms in the CYP2E1 gene
9. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles
10. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
11. Urinary excretion of codeine, ethylmorphine, and their metabolites: Relation to the CYP2D6 activity
12. The nuclear orphan receptor carvetinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene
13. Genetic polymorphism of human CYP2E1: Characterization of two variant alleles
14. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
15. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
16. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
17. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway
18. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
19. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
20. Why do so many drugs fail between the laboratory and the marketplace?
21. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase
22. Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism
23. Nicotine metabolism defect reduces smoking
24. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)
25. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
26. Genetic association between sensitivity to warfarin and expression of CYP2C9*3
27. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds